Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept
Weight & MetabolismSynthetic nonapeptide (delta sleep-inducing peptide)

Emideltide

Emideltide is studied as a synthetic nonapeptide (delta sleep-inducing peptide) in biochemical and physiological models.

UnapprovedPreclinical Models Only (Animal / Lab)Also known as: DSIP, Delta sleep-inducing peptideSkip to Human Evidence ↓
Other Research Areas

Emideltide Biological Classification

Research Record

Investigated within physiological and chemical models.

1

What is Emideltide?

Emideltide is classified as a synthetic nonapeptide (delta sleep-inducing peptide). A nonapeptide also known as DSIP. FDA uses the INN emideltide. No United States approved product. Discussed at PCAC on 24 July 2026 for nominated uses of opioid withdrawal, chronic insomnia and narcolepsy.

2

Why are people interested in it?

Researchers and clinicians study Emideltide primarily to understand its biological interactions, receptor binding affinity, and potential role within its biochemical class.

Primary Research Categories

  • Peptide fragments
  • Preclinical research compounds
3

How does it work in the body?

Emideltide interacts with specific cellular receptors and metabolic pathways corresponding to its structural classification as a synthetic nonapeptide (delta sleep-inducing peptide).

In Everyday Language: In laboratory settings, Emideltide interacts with specific cellular targets to modulate biological signaling pathways associated with synthetic nonapeptide (delta sleep-inducing peptide) biology.
Cellular & Receptor Signaling: Emideltide interacts with specific cellular receptors and metabolic pathways corresponding to its structural classification as a synthetic nonapeptide (delta sleep-inducing peptide).

Biological Pathway Overview

Emideltide Receptor & Target Interactions

This compound is evaluated in scientific research for its interactions with target cellular receptors and signaling cascades. Consult the evidence section below for specific peer-reviewed papers.

Target Pathway

Engages specific cellular signaling cascades characteristic of its structural family.

Endocrine/Paracrine Activity

Investigated for its regulatory effects on local tissue synthesis and cellular signaling.

4

What has actually been demonstrated in humans?

Preclinical Models Only (Animal / Lab)

Evidence for Emideltide is currently derived primarily from laboratory or preclinical models. Consult the published evidence file for specific indexed studies.

Pharmaceutical Reality vs. Unregulated Research Chemicals

Emideltide is not an FDA-approved medication. Always verify chemical identity and testing documentation before interpreting research literature.

5

What is still uncertain or unknown?

Controlled human clinical trials evaluating Emideltide for therapeutic efficacy, safety, and pharmacokinetics are limited or absent in peer-reviewed Western registries.

Regulatory Position: Emideltide is an investigational or unapproved compound. It is not approved by the FDA as a commercial pharmaceutical.

Companion Resources & Guides

Evidence Landscape→

Primary research publications and study designs indexed for Emideltide.

Research at a Glance

Open the full evidence file (3 records)

3 records in this file

  • ANIMAL1
  • REGULATORY2

Publication span: 1977–2026

What Has Actually Been Studied

  • FDA — bulk substances nominated for compounding and withdrawn: emideltide (DSIP) (FDA compounding communications, 2026) — FDA compounding classification.
  • FDA PCAC briefing — emideltide-related bulk drug substances (24 July 2026) (FDA PCAC briefing, 2026) — FDA advisory-committee briefing.
  • Characterization of a delta-electroencephalogram (-sleep)-inducing peptide (Proceedings of the National Academy of Sciences, 1977) — Isolation, synthesis and in-vivo rabbit EEG assay.

What is Still Unknown

What we know

  • Schoenenberger and Monnier 1977 characterised a rabbit-derived nonapeptide WAGGDASGE as delta-sleep-inducing peptide.
  • FDA uses the INN emideltide. No United States approved product. Withdrawn compounding nomination.
  • PCAC discussed emideltide-related bulk substances on 24 July 2026. FDA briefing materials proposed against inclusion. That is not a listing decision.

Editorial reading of the records below, labelled as Therapept analysis. How records are built

What remains uncertain

  • Whether an endogenous human DSIP of this sequence is established — later literature has debated that point.
  • Controlled human interventional data for the nominated uses (opioid withdrawal, insomnia, narcolepsy).

Preparation and Handling

Lyophilized peptides ship as freeze-dried powders; whatever happens next involves diluents, concentrations and storage conditions that are compound- and product-specific.

Preparation Resource HubWhat “lyophilized” meansConcentration calculator

United States Regulatory Status

No FDA-approved product

  • No approved drug product exists in Drugs@FDA.
  • Listed on FDA's table of bulk substances nominated for compounding and subsequently withdrawn, as emideltide (DSIP). Published concerns include immunogenicity risk and absence of identified safety information for the proposed route.
  • On 24 July 2026 PCAC discussed emideltide (free base) and emideltide acetate (uses evaluated: opioid withdrawal, chronic insomnia and narcolepsy). FDA briefing materials proposed that they NOT be included on the 503A Bulks List. Nominations had been withdrawn; FDA elected to proceed. Committee recommendations are non-binding; FDA has not published a listing decision as of this review.
Technical Chemical SpecificationsClick to view CAS, sequence, and molecular formulas
Molecular weight
848.8 g/mol
Sequence length
9 chars
CAS number
62568-57-4
PubChem CID
68816
Compound class
Synthetic nonapeptide (delta sleep-inducing peptide)
Sequence
WAGGDASGE
Molecular formula
C35H48N10O15
Molecular weight
848.8 g/mol
CAS number
62568-57-4
PubChem CID
68816